Sionna Therapeutics, Inc. Common Stock Asset Resilience Ratio
Sionna Therapeutics, Inc. Common Stock asset resilience ratio. Sionna Therapeutics, Inc. Common Stock (SION) has an Asset Resilience Ratio of 54.43% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sionna Therapeutics, Inc. Common Stock (SION) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sionna Therapeutics, Inc. Common Stock (2022–2025)
Asset resilience ratio of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. This chart shows how Sionna Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read SION current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sionna Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Sionna Therapeutics, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $177.43 Million | 54.43% |
| Total Liquid Assets | $177.43 Million | 54.43% |
Asset Resilience Insights
- Very High Liquidity: Sionna Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 54.43% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sionna Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Sionna Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Sionna Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2022–2025)
Sionna Therapeutics, Inc. Common Stock asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Sionna Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.43% | $177.43 Million | $325.95 Million | -4.65pp |
| 2024-12-31 | 59.08% | $109.75 Million | $185.75 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $51.95 Million | -- |
| 2022-12-31 | 31.79% | $27.77 Million | $87.37 Million | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more